Encapsualtion of pharmaceuticals inside nanoporous materials is of increasing interest due to their possible applications as new generation therapeutics, thernostic platforms or smart devices.
Introduction
Mesoporous silicas have attracted much interest in materials science due to unique features including synthetically controllable architecture of the pores and pore size diameter, large surface area and possible functionalisation of the silanol groups on the materials surface. [1] [2] [3] [4] [5] Recently, mesoporous silica nanoparticles have gained increasing importance for pharmaceutical applications as intracellular drug delivery systems or novel diagnostic platforms. 1, [6] [7] [8] [9] [10] [11] [12] Controllable encapsulation and manipulation of the drug phase under nanoscale confinement make these materials interesting as nanoscale crystallisation chambers for polymorph screening, leading to discoveries of new crystalline phases or stabilization of metastable crystals. 13, 14 For example Ward and co-workers demonstrated formation of new polymorphs of pimelic acid, suberic acid and coumarin when confined inside CPG material (controlled pore glass) with pore sizes lower than 23 nm. 13, 15 Selective crystallisation and stabilisation of metastable form of paracetamol (form III) was demonstrated by Beiner and co-workers inside the CPG with pore size (d) in the range from 22 nm to 103 nm and stabilisation of amorphous drugs inside smaller pores (below 10 nm). 16, 17 The investigation of structure and phase transitions of confined nanosize crystals using PXRD and DSC is far from trivial, due to a decrease of long range ordering in the materials, reflected in broadening of the PXRD peaks and decrease and broadening of the melting peak of confined crystals. 15, 17, 18 Furthermore, simultaneous presence of molecules in different physical states and motional regimes inside the mesopores makes detailed characterisation of such complex 3 composites very challenging. [18] [19] [20] Therefore, application of methods sensitive to the local environment of atoms (namely solid-state NMR) is of high importance for molecular-level understanding of crystallisation and phase transitions of pharmaceuticals. [21] [22] [23] [24] Recently we have demonstrated controllable crystallisation and stabilisation of metastable indomethacine form V inside the 30 nm pores of MCF material (Mesoporous Cellular Foam). 18 Furthermore, we developed a 19 F MAS NMR protocol to probe the local environment of confined flufenamic acid in situ and showed for the first time the simultaneous presence of confined molecules as nanocrystalline, amorphous and highly mobile species adsorbed at the silica surface during confined crystallisation. 21 A recent study of Navrotsky and co-workers demonstrated crystallisation of the iodide salt of the rigid, spherical organic ion N,N,N-trimethyl-1adamantammonium (TMAAI, 321,3 g mol -1 ) within 12.8 nm pores of SBA-15 type silica and the coexistence of crystalline and amorphous species inside the pores using 13 C MAS NMR and selectively labelled ( 13 C) TMAAI. 25 Furthermore, the authors indicated that a pore size of at least one unit cell and temperature below the (depressed) melting point can serve as sufficient indicators of the formation of confined nanocrystals. 25 This is in agreement with the crystallisation of ibuprofen (206.3 g mol -1 ) confined within 11.6 nm pores of SBA-15 at 223 K reported by Azais et al. 26 Based on our previous findings 18, 21 and the recent report from Navrotsky's group 25 , we have selected a small and flexible molecule (tolbutamide, 270.35 g mol -1 ) as a model to probe hypothesis that size and flexibility of organic molecules, together with high loading levels within the pores play an essential role in the successful crystallisation of pharmaceuticals inside porous hosts even with relatively narrow mesopores. Tolbutamide (TB) contains a rigid benzene ring and a highly mobile aliphatic chain with seven bonds that can rotate freely. The high flexibility of this structure 4 has led to a large number of TB polymorphs reported in the Cambridge Structural Database (7 structures including a high Z' form III). [27] [28] [29] [30] [31] [32] Due to its high flexibility, TB adopts different conformations in different crystal forms making it a representative example of conformational polymorphism. 27 Furthermore, due to its low glass transition temperature (Tg = 277 K) and crystallisation during cooling of the molten drug it is a challenging material to be stabilised in its amorphous state. [33] [34] [35] [36] Using several complementary techniques (N2 adsorption, PXRD, DSC and solid-state NMR), we have demonstrated that TB can be encapsulated within the pores of MCM-41 silica host with relatively narrow mesopores (diameter ca. 3.2 nm, much smaller than that for SBA-15, MCF or CPG silicas) using melt loading method. Through the gradual increase of the guest content we have achieved gradual filling of the pores and showed that the model drug can be successfully stabilised in it amorphous state at drug loadings up to 30 wt% or its crystallisation can be directed into metastable form V as confirmed using PXRD and solid-state NMR corroborated by DFT calculations. As previously reported by Nath et al., TB form V could only be obtained using crystallisation from acidified methanol and it is stable for only few hours at room temperature. 29 In this work we demonstrate for the first time crystallisation of metastable TB form V inside the pores of MCM-41 (3.2 nm) silica scaffold and also report in-situ monitoring of its phase transition to TB form I H using solid-state NMR.
Experimental Section

Materials and Synthetic protocols
Materials
Tolbutamide, n-hexadecyltrimethylammonium bromide, ammonia, ethanol, tetraethyl orthosilicate (TEOS), methanol were all purchased from Sigma-Aldrich.
Synthesis of MCM-41
Spherical, homogenous MCM-41 particles were synthesised according to the method previously published by Grün et al. 37 In a typical synthesis, 2.5 g of n-hexadecyltrimethylammonium was dissolved in miliQ quality water (50 mL). A solution of ammonia (37% wt., 13.2 g) and ethanol (60 g) was mixed with the already prepared n-hexadecyltrimethylammonium solution. The solution was stirred for 15 minutes and 4.7 g of TEOS was added, resulting in a mixture of the following composition: 1 TEOS: 0.3 C16TMABr: 11 NH3: 144 H2O: 58 EtOH. After stirring for 2 hours, a precipitate was formed, filtered and washed using methanol and deionized water. The material was dried at 363 K overnight and calcined at 823 K for 5 hours.
Drug loading
TB (guest) was loaded into MCM-41 (host) using the melt loading method. Briefly, the drug and the host were mixed in a glass vial for 3 minutes using a spatula in host:guest ratios of 85:15, 80:20, 75:25, 70:30, 60:40 and 50:50 (wt/wt). The obtained mixture of the powders was heated on a hot plate at 408 K, i.e. above the melting point of TB, and mixed with spatula for 5 minutes, ensuring that the drug can be adsorbed within the pores via capillary action. Once loaded, the samples were cooled to room temperature and stored within a desiccator.
Characterisation methods
Differential scanning calorimetry (DSC)
DSC analysis was carried out using a Q2000 MTDSC instrument (TA Instruments, New Castle, DE, US). Crimped aluminium pans were used for all analyses. The sample weights ranged from 2-4 mg for pure crystalline samples, and 8-10 mg for loaded drug:silica composites. A nitrogen 6 flow rate of 50 mL/min was used. The sample was heated with a heating rate of 5 K/min from 253 to 408 K followed by cooling with 20 K/min to 253 K and subsequent heating with a heating rate of 5 K/min to 408 K. The data were analysed using the TA Instruments Universal Analysis 2000 software (TA Instruments-Waters LLC).
Thermogravimetric analysis (TGA)
A TQ500 thermogravimetric analyser (TA Instruments, New Castle, DE, US) was used to determine the drug content within the composites. The samples (weight 5-10 mg) were heated at a rate of 5 K/minute from 298 K to 373 K to determine content of water adsorbed within the material and then further with heating rate of 30 K/minute to 873 K. The sample was kept at 873 K for 15 minutes to ensure complete decomposition of the drug and then heated to 903 K. The samples were then cooled to room temperature. The analysis was performed in an inert gas atmosphere with 50 mL/min purge of N2. TA Instruments Universal Analysis 2000 software (TA Instruments-Waters LLC) was used to analyse the data.
Powder x-ray diffraction (PXRD)
ARL TM X'TRA Powder Diffractometer (Thermo Fisher Scientific Inc., Waltham, MA, US) was used with Cu Kα radiation with a wavelength of 0.15424 nm. The composites were analysed in the angular range 2θ from 6-36° and the step size of 0.01° using scanning rate of 6 seconds per step. The analysis was performed at room temperature.
Scanning electron microscopy (SEM)
The SEM images of the synthesized material were taken using a JSM 4900 LV microscope (JEOL Ltd, Japan) at 20 kV. Prior to the analysis the samples were sputtered with thin film of gold.
Nitrogen adsorption-desorption analysis
Nitrogen adsorption-desorption isotherms were measured using a Nova 2200e Surface Area and Pore Size Analyzer (Quantachrome, Hook, UK) at 77 K. All samples were outgassed under a high vacuum at 313 K for 12 h prior to the analysis to avoid any temperature driven recrystallization of the loaded drug. The BET specific surface area was calculated over a relative pressure range from 0.05 to 0.20 assuming monolayer coverage and a molecular area of the nitrogen of 0.162 nm 2 . The pore size distribution curves were calculated by applying the NLDFT method implemented in the NovaWin (ver. 11.03) software (Quantachrome Instruments) using spherical/cylindrical pore model and N2 adsorption on silica at 77 K.
Nuclear magnetic resonance spectroscopy (NMR)
All solid-state NMR spectra were acquired using a Bruker AVANCE III solid-state NMR spectrometer with a Larmor frequency of 400.23 MHz for 1 H and 100.64 MHz for 13 experiments were performed in the temperature range from 293 to 373 K in 10 K steps. The temperature of the sample was stabilised for 5 min before spectra acquisition. The temperature 8 control was achieved using a Bruker BCU II chilling unit and a standard heater implemented in the probe. 1 H Solution-state NMR spectra of TB were recorded using Bruker Avance I spectrometer equipped with a triple resonance probe operating at 499.69 MHz for 1 H. The obtained spectra corroborated by online spectra predictor 38 and CASTEP calculations were used for 1 H assignment. 1 H and 13 C NMR chemical shift calculations using first principles. Computations were performed using the CASTEP code. 39 Geometry optimisation was carried out with constrained cell parameters and positions of all heavy atoms using the PBE exchange-correlation functional 40 The NMR chemical shieldings were calculated using the gauge including projector augmented wave approach (GIPAW) 43 and a cut-off energy of 1100 eV. The isotropic NMR shieldings computed with CASTEP were converted to chemical shifts using the following equation:
where σi so is the isotropic chemical shielding generated from first-principles calculations and σref = step is presented in black and desorption step is presented in white points in the isotherms. nm were loaded with tolbutamide using the melting method. Loaded composites analysed with nitrogen adsorption/desorption isotherms show a gradual decrease of the total pore volume and surface area with increasing drug content ( Figure 1 , Table 1 ). These results are corroborated by low angle PXRD, where gradual attenuation of the d[100] reflections is observed with increasing drug content ( Figure 2 ). This may be attributed to a reduction in the X-ray scattering contrast between the silica walls and the pore filling material and not to a loss of crystallinity of the MCM-41 host. 45 Thermogravimetric analysis of the drug-SiO2 composites confirmed that the expected drug content was achieved during loading and loading temperature was below the thermal degradation point of the drug (see ESI Figure S2 ). It is important to mention that water content of final composites was low and ca. 1-2 wt. % as determined by TGA. 
Formation of confined metastable form V of TB
11
Amorphous tolbutamide has low glass transition temperature (Tg = 277 K) and is included in the first class of glass forming agents based on the classification system implemented by Taylor et al. 35 Compounds in this class recrystallise during cooling from the undercooled melt state, regardless of cooling rate. 35, 36 Based on the results reported by Kawakami et al. 36 , supercooled TB recrystallises to form IV on cooling, with a further recrystallisation to form III observed during subsequent heating. The observed TB form V has only been formed previously through crystallisation from acidified methanol. 29 The obtained TB form V encapsulated within the mesoporous silica host was stable for at least one month when stored in a desiccator over a silica gel at RT as compared to couple of hours reported by Nath et al. 29 for bulk TB form V (See ESI Figure S5 ). DSC analysis ( Figure 3B with the 13 C chemical shifts calculated with CASTEP, based on the ZZZPUS10 29 structure reported recently in the CSD. 49 Additionally, a decrease in the peak intensity of the amorphous TB (6144 scans) as compared to crystalline TB (1024 scans) may indicate increased mobility of the confined amorphous drug, resulting in the inefficient transfer of magnetisation during the crosspolarisation. 50 We recently observed similar phenomenon for flufenamic acid 21 and indomethacin 18 confined within mesoporous silica materials with pore sizes from 3.2 to 30 nm and lactose 51 intercalated within sodium montmorillonite nanocomposites. These findings are in agreement with data presented by Azais et al. 26, 52 and Buntkowsky and co-workers. 53 Furthermore, our data are consistent with the results of computational studies of encapsulation of ibuprofen or clotrimazole in MCM-41 silicas postulating the presence of a highly dynamic adsorbed layer of the drug at the surface of the pores. 54 Figure 4E ).
In situ monitoring of phase transitions of TB under confinement via solid-state NMR.
The investigation of phase transitions of confined solids is a considerable analytical challenge due to decrease and broadening of the melting peak in DSC and broadening of PXRD peaks for nano-size crystals. 13, 14, 59 In such cases, full understanding of the phase transitions in confinement requires application of methods sensitive to the local environment of atoms, therefore solid-state NMR is ideal to probe both structure and dynamics. that there is a narrow temperature range at which TB form I H can be present before it melts at 366 K. When the temperature reached 373 K, the confined drug melted. This was confirmed firstly by a loss of the CP efficiency observed as a substantial decrease of the peaks intensity in the 1 H-13 C CP/MAS spectrum ( Figure 5A ), and secondly by the significant narrowing of lines in the 1 H spectrum at 373 K, due to an increased mobility ( Figure 5B ). When the material is cooled to 293 K the 1 H-13 C CP/MAS NMR spectrum shows broad peaks characteristic of amorphous TB.
The VT 1 H MAS spectra of the MCM-TB 50-50 composite with confined TB form V showed a gradual narrowing of proton peaks H1, H3, H4, H6 and H7 with increasing temperature. The gradual narrowing of the peaks was attributed to increased dynamics of the aromatic ring of tolbutamide with increasing temperature. This is not unexpected as all TB polymorphs are stabilised through the rigid sulfonylurea bonding motif, hence the aromatic ring of tolbutamide may be in a different motional regime compared to the aliphatic part of the molecule.
Conclusions
We demonstrated that the drug content inside the pores is an important factor in directing formation of confined nanocrystals for very flexible TB guest species. 
